Results 211 to 220 of about 4,669,551 (309)

Pigment Cell, Volume I, Mechanisms in Pigmentation

open access: yesJournal of Investigative Dermatology, 1974
openaire   +1 more source

Potential for Carotenoid and Other Bioproducts Production by a Brazilian Dunaliella salina Isolate Using a High Photon Flux Density Strategy

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Dunaliella species are among the most significant biological sources of carotenoids, notably beta‐carotene. Given that chemical synthesis offers a more cost‐effective alternative to biotechnological cultivation, optimizing production strategies is essential for economic viability.
Camylle Guimarães Scheliga   +3 more
wiley   +1 more source

Bioeconomy, sustainability, and digital technologies in Haematococcus lacustris biomass and astaxanthin production: advances and outlook

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Astaxanthin is a carotenoid with strong antioxidant properties, used in research on cancer treatment, ocular injuries, and neurological disorders. When produced by the microalgae Haematococcus lacustris, its antioxidant potential is even higher than that of the synthetic molecule, making it particularly attractive for pharmaceutical and ...
Renata Kühl Rocha   +5 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy